Empowering investors with access to the best research, experts and opportunities.
Equity markets around the globe have bled after yet another supersized 75bps rate hike by the Fed, bringing the current US federal funds rate target up to 3%-3.25%, the highest since 2008, and blowing out 2023 projections to 4.6%.
Great white sharks are swimming in increasing numbers along the WA coastline, as well as increasingly close to shore, so it’s little surprise the WA Government has again turned to an Aussie company to install solar-powered tagged-shark detection receivers in the region.
ASX-listed biotech Prescient Therapeutics has unveiled the second component of its CellPryme cell therapy enhancement platform on stage at the prestigious CAR-TCR Summit in Boston.
Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In April, Yarra Capital Management’s Joel Fleming selected Probiotec as one of his favourite stocks, noting its potential for strong cash flow…
Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In May, Katana Asset Management’s Romano Sala Tenna selected Pepper Money as one of his favourite stocks, noting its first-rate management and…
If ever an investment group embodied the phrase ‘an oldie but a goodie’, it’s Hancock & Gore – from its roots as a blossoming sawmill business in 1867 to its market-outperforming status in modern times.
Global markets are on tenterhooks ahead of the release of the US Federal Open Market Committee’s latest interest rate decision, due early Thursday morning (Australian time).
Investors are known for their interest in future tech and their appreciation of fine art – but would the love remain if these areas were combined? One enterprising CEO may have the answer.
Just over a week after the Indonesian Government granted its approval in a milestone decision, the first-ever drill rig to enter Woyla has been fired up and drilling has begun at the highly prospective copper-gold project.
The Australian pharma landscape is in for a notable change with the down-scheduling of low-dose cannabidiol (CBD) products to Schedule 3 (S3) or ‘pharmacist only medicine’ – and one health and wellness innovator’s proven capability to take brands to market ‘first and fast’ puts it in a unique position to be a pioneer in the industry.
There’s about a 50-50 chance you’ll get cancer at some point. Already the world’s second leading cause of death and of years of life lost, the global cancer burden is expected to grow 47% between 2020 and 2040, to about 29 million cases annually.
Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In April, Yarra Capital Management’s Joel Fleming selected Calidus Resources as one of his favourite stocks, noting its potential for strong cash…
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.